The Medical Letter on Drugs and Therapeutics
Natalizumab (Tysabri) for Crohn's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 5/29/08:
Adverse Effects, 2nd sentence has been changed from “...hepatic toxicity, sometimes fatal or requiring liver transplantation, has occurred.” to: “...hepatic toxicity that could lead to death or the need for a liver transplantation in some patients has occurred.”
Conclusion, last sentence has been changed from “...leukoencephalopathy, it is FDA-approved for use only in...” to: “...leukoencephalopathy, it should be used only in...”

Natalizumab (Tysabri – Elan and Biogen) is a monoclonal antibody approved for induction and maintenance treatment of moderate to severe Crohn’s disease (CD) refractory to conventional therapies and inhibitors of tumor necrosis factor (TNF). Initially approved in 2004 for the treatment of multiple sclerosis (MS), natalizumab was temporarily withdrawn from the market after 3 patients developed progressive multifocal leukoencephalopathy (PML).1 It is now available for treatment of both MS and CD through a restricted distribution program.

TREATMENT OF CROHN’S DISEASE — An amino salicylate such as mesalamine (Asacol, Pentasa), designed to be released only in the distal ileum and colon and/or an antibiotic such as ciprofloxacin (Cipro, and others) or metronidazole (Flagyl, and others) is the usual first-line treatment for mild to moderate active Crohn’s ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Natalizumab (Tysabri) for Crohn's Disease
Article code: 1285b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian